Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• Multiple myeloma (MM) is a cancer of plasma cells.
• Hematopoietic stem cell transplantation (HSCT) is a complex treatment option for eligible MM patients.
• Caregivers play a vital role throughout the HSCT journey.

Purpose of the Study:

• To offer a comprehensive overview of the hematopoietic stem cell transplantation (HSCT) process.
• To provide specific insights relevant to patients with multiple myeloma (MM) and their caregivers.
• To enhance understanding among healthcare professionals, particularly nurses, regarding HSCT in MM.

Main Methods:

• Literature review encompassing research studies and expert knowledge.
• Synthesis of information from book chapters, websites, and journal articles.
• Compilation of current best practices and established knowledge in HSCT for MM.

Main Results:

• Autologous HSCT, while not curative, is a significant and manageable treatment for MM.
• It remains a standard of care for eligible multiple myeloma patients.
• The HSCT process involves multiple stages requiring careful management and support.

Conclusions:

• Autologous HSCT is an established and manageable treatment modality for multiple myeloma.
• Nurses caring for MM patients benefit from understanding the HSCT process, even if it's a specialty practice.
• This knowledge empowers nurses to provide better support to patients and their caregivers undergoing HSCT.